Elanco Animal Health Incorporated (ELAN) Key Metrics
ELAN valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $11.76B
- Enterprise value
- $14.66B
- P/E (TTM)
- — 10-yr median 114.3
- Forward P/E
- 17.4
- PEG ratio
- 4.04
- Price / sales
- 2.3 10-yr median 2.6
- Price / book
- 1.7 10-yr median 1.7
- EV / EBITDA
- 18.9 10-yr median 24.4
- Dividend yield
- —
- Beta
- 1.71
ELAN key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsELAN valuation Price multiples at each fiscal year-end price.
Price / sales+75.6%
2.4
2025 · hover or tap a bar for each year
20162025
Price / book+73.7%
1.7
2025 · hover or tap a bar for each year
20162025
EV / EBITDA+228.0%
21.8
2025 · hover or tap a bar for each year
20162025
Price / free cash flow+158.8%
39.6
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−4.0 pts
2.5%
2025 · hover or tap a bar for each year
20162025
ELAN returns How much profit the business earns on the capital it uses.
Return on equity−9.2 pts
−3.7%
2025 · hover or tap a bar for each year
20162025
Return on invested capital+0.4 pts
2.0%
2025 · hover or tap a bar for each year
20162025
Return on assets−4.3 pts
−1.8%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin−2.9 pts
6.0%
2025 · hover or tap a bar for each year
20162025
Asset turnover+10.3%
0.36
2025 · hover or tap a bar for each year
20162025
ELAN per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+6.4%
$9.50
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.47
2025 · hover or tap a bar for each year
20162025
Free cash flow per share−27.8%
$0.57
2025 · hover or tap a bar for each year
20162025
Book value per share+7.6%
$13.19
2025 · hover or tap a bar for each year
20162025
Shares outstanding−0.2%
496.4M
2025 · hover or tap a bar for each year
20162025
ELAN financial health Debt, liquidity and how easily interest is covered.
Debt / equity−13.4%
0.61
2025 · hover or tap a bar for each year
20162025
Net debt−$381.0M
$3.47B
2025 · hover or tap a bar for each year
20162025
Net debt / EBITDA+2.55
5.14
2025 · hover or tap a bar for each year
20162025
Current ratio−11.4%
2.17
2025 · hover or tap a bar for each year
20162025
Interest coverage+54.7%
1.1
2025 · hover or tap a bar for each year
20162025
Debt / assets−12.2%
0.30
2025 · hover or tap a bar for each year
20162025
ELAN efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−7 days
71 days
2025 · hover or tap a bar for each year
20162025
Days of inventory−12 days
227 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+5 days
45 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−24 days
252 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+2.5 pts
5.9%
2025 · hover or tap a bar for each year
20162025
ELAN valuation history
Fiscal year-endToday10-year median
ELAN returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ELAN debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ELAN price vs earnings per share
Share price at year-endEPS (right axis)
ELAN key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $11.23B | $6.02B | $7.34B | $5.97B | $13.83B | $13.54B | $10.91B | $9.89B | — | — |
| Enterprise value | $14.71B | $9.88B | $12.76B | $11.46B | $19.51B | $19.17B | $12.93B | $11.89B | — | — |
| P/E ratio | — | 17.8 | — | — | — | — | 160.6 | 114.3 | — | — |
| Price / sales | 2.4 | 1.4 | 1.7 | 1.4 | 2.9 | 4.1 | 3.6 | 3.2 | — | — |
| Price / book | 1.7 | 1.0 | 1.2 | 0.8 | 1.8 | 1.6 | 2.0 | 1.9 | — | — |
| Price / free cash flow | 39.6 | 15.3 | 62.7 | 22.3 | 48.3 | — | 408.4 | 28.0 | — | — |
| Price / operating cash flow | 20.1 | 11.1 | 27.1 | 13.2 | 28.6 | — | 48.7 | 20.3 | — | — |
| EV / sales | 3.1 | 2.2 | 2.9 | 2.6 | 4.1 | 5.9 | 4.2 | 3.9 | — | — |
| EV / EBITDA | 21.8 | 6.6 | — | 13.2 | 47.7 | — | 27.4 | 27.0 | — | — |
| EV / free cash flow | 51.8 | 25.1 | 109.0 | 42.8 | 68.2 | — | 484.1 | 33.7 | — | — |
| Earnings yield | −2.1% | 5.6% | −16.8% | −1.3% | −3.5% | −4.1% | 0.6% | 0.9% | — | — |
| Free cash flow yield | 2.5% | 6.5% | 1.6% | 4.5% | 2.1% | −2.6% | 0.2% | 3.6% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | — | — | 0.0% | — | 0.0% | — | — |
| Share price at fiscal year-end | $22.63 | $12.11 | $14.90 | $12.22 | $28.38 | $30.67 | $29.45 | $31.53 | — | — |
| Per share | ||||||||||
| Revenue per share | $9.50 | $8.93 | $8.97 | $9.03 | $9.78 | $7.42 | $8.29 | $9.78 | $8.11 | $8.18 |
| Earnings per share | −$0.47 | $0.68 | −$2.50 | −$0.16 | −$0.99 | −$1.27 | $0.18 | $0.28 | −$0.87 | −$0.13 |
| Operating cash flow per share | $1.13 | $1.09 | $0.55 | $0.93 | $0.99 | −$0.09 | $0.61 | $1.55 | $0.49 | $0.44 |
| Free cash flow per share | $0.57 | $0.79 | $0.24 | $0.55 | $0.59 | −$0.80 | $0.07 | $1.12 | $0.21 | $0.13 |
| Cash per share | $1.10 | $0.94 | $0.72 | $0.71 | $1.31 | $1.12 | $0.90 | $1.51 | $0.91 | $0.73 |
| Book value per share | $13.19 | $12.26 | $12.64 | $14.93 | $15.41 | $19.20 | $14.98 | $16.57 | $21.87 | $19.73 |
| Tangible book value per share | −$3.30 | −$4.02 | −$6.84 | −$7.26 | −$8.73 | −$9.37 | $0.20 | −$0.68 | $6.03 | $5.14 |
| Capex per share | $0.56 | $0.30 | $0.31 | $0.38 | $0.40 | $0.70 | $0.53 | $0.43 | $0.28 | $0.31 |
| Debt per share | $8.09 | $8.69 | $11.73 | $11.95 | $12.97 | $13.88 | $6.36 | $7.88 | — | — |
| Shares outstanding | 496.4M | 497.3M | 492.3M | 488.3M | 487.2M | 441.4M | 370.3M | 313.7M | 356.2M | 356.2M |
| Change in shares outstanding | −0.2% | +1.0% | +0.8% | +0.2% | +10.4% | +19.2% | +18.0% | −11.9% | 0.0% | 0.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −3.7% | 5.5% | −18.2% | −1.1% | −6.0% | −8.0% | 1.3% | 1.3% | −4.2% | −0.7% |
| Return on invested capital (ROIC) | 2.0% | 1.6% | 2.1% | 2.3% | 1.8% | −0.6% | 4.4% | 3.2% | 1.6% | 3.3% |
| Return on assets (ROA) | −1.8% | 2.5% | −8.2% | −0.5% | −2.8% | −4.2% | 0.8% | 1.0% | −3.6% | −0.6% |
| Return on tangible assets | −4.5% | 7.5% | −25.8% | −1.7% | −10.2% | −11.0% | 1.9% | 2.4% | −9.4% | −1.7% |
| Free cash flow margin | 6.0% | 8.9% | 2.6% | 6.1% | 6.0% | −10.8% | 0.9% | 11.5% | 2.6% | 1.6% |
| Income quality (OCF / net income) | — | 1.60 | — | — | — | — | 3.30 | 5.63 | — | — |
| Financial health | ||||||||||
| Total debt | $4.02B | $4.32B | $5.77B | $5.84B | $6.32B | $6.13B | $2.35B | $2.47B | — | — |
| Cash & short-term investments | $545.0M | $468.0M | $352.0M | $345.0M | $638.0M | $495.0M | $334.0M | $474.8M | $323.4M | $258.8M |
| Net debt | $3.47B | $3.85B | $5.42B | $5.49B | $5.68B | $5.63B | $2.02B | $2.00B | −$323.4M | −$258.8M |
| Debt / equity | 0.61 | 0.71 | 0.93 | 0.80 | 0.84 | 0.72 | 0.42 | 0.48 | — | — |
| Debt / assets | 0.30 | 0.34 | 0.40 | 0.38 | 0.38 | 0.35 | 0.26 | 0.28 | — | — |
| Net debt / EBITDA | 5.14 | 2.59 | — | 6.34 | 13.89 | — | 4.29 | 4.54 | −3.77 | −1.12 |
| Current ratio | 2.17 | 2.44 | 2.75 | 1.93 | 1.99 | 1.65 | 2.90 | 2.58 | 3.36 | 3.15 |
| Quick ratio | 1.08 | 1.25 | 1.35 | 1.02 | 1.16 | 0.89 | 1.62 | 1.55 | 1.68 | 1.73 |
| Interest coverage | 1.1 | 0.7 | 1.2 | 1.5 | 1.2 | -0.5 | 4.7 | 10.6 | — | — |
| Working capital | $1.86B | $1.90B | $2.17B | $1.58B | $1.63B | $1.34B | $1.55B | $1.53B | $1.49B | $1.33B |
| Invested capital | $10.02B | $9.95B | $11.64B | $12.78B | $13.19B | $14.11B | $7.57B | $7.20B | $7.47B | $6.77B |
| Tangible asset value | −$1.64B | −$2.00B | −$3.37B | −$3.55B | −$4.25B | −$4.14B | $74.5M | −$213.5M | $2.15B | $1.83B |
| Net current asset value | −$3.35B | −$3.30B | −$4.73B | −$4.92B | −$5.70B | −$5.80B | −$1.07B | −$1.25B | $974.2M | $875.6M |
| Graham number | — | $13.69 | — | — | — | — | $7.86 | $10.14 | — | — |
| Graham net-net per share | −$9.45 | −$9.25 | −$12.52 | −$12.98 | −$14.11 | −$16.14 | −$5.16 | −$7.17 | $0.44 | $0.27 |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | $0 | — | $0 | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | 0.0% | — | — |
| Capex / revenue | 5.9% | 3.3% | 3.5% | 4.2% | 4.1% | 9.5% | 6.4% | 4.4% | 3.4% | 3.8% |
| Capex / operating cash flow | 49.3% | 27.2% | 56.8% | 40.7% | 40.8% | — | 88.1% | 27.6% | 56.7% | 70.8% |
| Capex / depreciation | 0.41 | 0.22 | 0.22 | 0.27 | 0.28 | 0.60 | 0.63 | 0.45 | 0.31 | 0.43 |
| Stock-based compensation / revenue | 1.4% | 1.2% | 1.0% | 1.3% | 1.4% | 1.4% | 1.6% | 0.8% | 0.9% | 0.7% |
| R&D / revenue | 7.8% | 7.7% | 7.4% | 7.3% | 7.7% | 10.0% | 8.8% | 8.0% | 8.7% | 9.1% |
| SG&A / revenue | 30.3% | 29.6% | 29.0% | 28.7% | 29.5% | 30.4% | 24.8% | 24.0% | 27.0% | 26.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 70.7 | 77.9 | 83.1 | 84.0 | 80.6 | 109.7 | 95.0 | 78.0 | 77.9 | 79.0 |
| Days of inventory on hand | 226.7 | 238.7 | 241.0 | 217.5 | 200.2 | 236.7 | 224.5 | 212.9 | 206.2 | 202.3 |
| Days payables outstanding | 45.5 | 40.8 | 48.6 | 60.3 | 62.3 | 65.2 | 46.7 | 42.1 | 46.0 | 52.7 |
| Cash conversion cycle (days) | 251.9 | 275.8 | 275.5 | 241.2 | 218.6 | 281.2 | 272.8 | 248.8 | 238.1 | 228.6 |
| Receivables turnover | 5.16 | 4.68 | 4.39 | 4.35 | 4.53 | 3.33 | 3.84 | 4.68 | 4.69 | 4.62 |
| Payables turnover | 8.03 | 8.94 | 7.51 | 6.06 | 5.86 | 5.60 | 7.81 | 8.66 | 7.94 | 6.92 |
| Inventory turnover | 1.61 | 1.53 | 1.51 | 1.68 | 1.82 | 1.54 | 1.63 | 1.71 | 1.77 | 1.80 |
| Asset turnover | 0.36 | 0.33 | 0.30 | 0.28 | 0.28 | 0.25 | 0.34 | 0.34 | 0.34 | 0.36 |
| Average receivables | $913.0M | $948.0M | $1.01B | $1.01B | $1.05B | $983.5M | $799.6M | $655.6M | $616.3M | $630.7M |
| Average payables | $332.0M | $283.0M | $330.0M | $403.0M | $458.5M | $361.8M | $213.9M | $204.5M | $216.0M | $228.2M |
| Average inventory | $1.66B | $1.65B | $1.64B | $1.45B | $1.47B | $1.31B | $1.03B | $1.03B | $969.0M | $875.6M |
| Intangibles / total assets | 61.3% | 64.2% | 66.8% | 69.9% | 71.4% | 71.3% | 60.9% | 60.4% | 63.1% | 64.2% |
Computed from ELAN's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ELAN valuation and financial ratios
Elanco Animal Health earned a return on equity of −3.7% and a return on invested capital of 2.0% in fiscal 2025. It ended the year with $4.0 billion of debt and $545.0 million in cash and short-term investments, net debt of $3.5 billion. The share count rose 39.4% from 356.2M to 496.4M over 9 years.
See the ELAN income statement, the ELAN chart for price history, or the ELAN stock overview for the latest quote and news.
ELAN key metrics FAQ
What is Elanco Animal Health's EV/EBITDA?
Elanco Animal Health's enterprise value was 21.8 times EBITDA at the end of fiscal 2025 (enterprise value $14.7 billion, EBITDA $676.0 million); the current EV/EBITDA is 18.9.
What is Elanco Animal Health's return on equity?
Elanco Animal Health's return on equity (ROE) was −3.7% in fiscal 2025: net income of -$232.0 million on average shareholders' equity of $6.3 billion.
What is Elanco Animal Health's ROIC?
Elanco Animal Health's return on invested capital was 2.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Elanco Animal Health have?
Elanco Animal Health had total debt of $4.0 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.61 and $3.5 billion of net debt (5.14 times EBITDA).
What is Elanco Animal Health's free cash flow yield?
Elanco Animal Health generated $284.0 million of free cash flow in fiscal 2025, a free cash flow yield of 2.5% on its market value at year-end ($11.2 billion).
What is Elanco Animal Health's current ratio?
Elanco Animal Health's current ratio was 2.17 at the end of fiscal 2025: current assets were 2.17 times current liabilities.